Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-007: MK-1084 + MK-3475A vs MK-3475A + chemotherapy in KRAS G12C-mutant nonsquamous NSCLC
jRCT2031250409Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of calderasib, pembrolizumab, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival in PD-L1 positive participants. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250409.